We are live on ! Find out more
SWTX icon

SpringWorks Therapeutics

Delisted

SWTX was delisted on the 30th of June, 2025.

135 hedge funds and large institutions have $2.79B invested in SpringWorks Therapeutics in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 51 increasing their positions, 46 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

211% more capital inflows, than outflows

Capital inflows: $335M | Capital outflows: $108M

17% more funds holding in top 10

Funds holding in top 10: 6 → 7 (+1)

12% more call options, than puts

Call options by funds: $33.6M | Put options by funds: $29.9M

11% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 46

7.96% more ownership

Funds ownership: 92.29% → 100.26% (+8%)

6% less funds holding

Funds holding: 144 → 135 (-9)

39% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 23

Holders
135
Holders Change
-9
Holders Change %
-6.25%
% of All Funds
2.12%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.11%
New
14
Increased
51
Reduced
46
Closed
23
Calls
$33.6​M
Puts
$29.9​M
Net Calls
+$3.66​M
Net Calls Change
+$6.36​M

SWTX Hedge Fund Activity: Q1 2022 in Review

135 of the 6,363 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q1 2022, worth a combined $2.79B — down 0.9% from $2.82B a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of SWTX and 14 opened new positions — a net loss of 9 holders — while 46 trimmed existing stakes and 51 added.

The largest buyer was Fidelity Investments, adding an estimated $120M. The largest seller was Perceptive Advisors, cutting an estimated $18.4M.

  • 135 institutional investors held SpringWorks Therapeutics (SWTX) as of Q1 2022, down from 144 in Q4 2021.
  • Funds reported $2.79B of SpringWorks Therapeutics stock for Q1 2022, down 0.9% quarter-over-quarter.
  • 14 funds opened new SpringWorks Therapeutics positions in Q1 2022 and 23 closed out, a net change of -9 holders.
  • The largest SpringWorks Therapeutics buyer in Q1 2022 was Fidelity Investments, an estimated $120M added.
  • The largest SpringWorks Therapeutics seller in Q1 2022 was Perceptive Advisors, an estimated $18.4M sold.

Based on aggregated 13F filings for Q1 2022.